Pot shares surge as federal legalization looms
CNBC’s Frank Holland stories on the surge in cannabis shares amid the pandemic and how CEOs are focused on the future panorama. For accumulate entry to to dwell and uncommon…
Total gross sales sturdy despite vaping crisis: Cannabis investor
Matt Hawkins of Entourage End Capital joins CNBC’s “Energy Lunch” team to discuss how the vaping epidemic is impacting cannabis investing.
‘We’re seeing wallet pressure across the nation’ in spite of solid inquire of of: Trulieve CEO Kim Rivers
Trulieve CEO Kim Rivers joins ‘Instant Money’ to talk about quarterly earnings, the reveal of the U.S. cannabis market, and the legislation on cannabis banking sitting in the Senate. For…
Senate hearing on cannabis trade and banking challenges – 07/23/2019
The Senate Banking, Housing and Metropolis Affairs Committee holds a hearing on cannabis trade and banking challenges. » Subscribe to CNBC TV: n» Subscribe to CNBC: C» Subscribe to CNBC…
Cannabis replace exploding with hiss right here, says top pot exec
The cannabis replace is rising admire a weed, at the same time as pot stocks stare wild swings. With Smoke Wallin, Vertical Companies, CNBC’s Scott Wapner and the Rapidly Cash…
GW Pharma CEO: Need to take dangle of extra on advantages of cannabis-derived remedy
GW Pharmaceuticals CEO Justin Gover tell about the must know extra about what cannabis-derived remedy must provide with Jim Cramer.
Hashish stocks surge on legalization hopes — Here’s why
Vivien Azer, Cowen and Company, joins ‘Energy Lunch’ to talk concerning the surge in cannabis stocks as traders take a seat up for legalization if there’s a Biden presidency. Subscribe…
There’s excitement around that possibilities are you’ll maybe maybe also imagine policy change in U.S. cannabis: Analyst
Michael Lavery, Piper Sandler senior evaluation analyst, joins ‘Energy Lunch’ to dispute about the bull case for pot stocks and why retail merchants are attracted to the sector. For rep…
GW Pharma CEO on recent cannabis-derived drug
GW Pharmaceuticals CEO Justin Gover discusses how the company secured FDA approval for its cannabis-derived drug and what it says referring to the capacity forward for cannabis-derived treatment.
Pot shares working excessive—Here’s how or no longer it’s affecting these ETFs
CNBC’s Frank Holland breaks down how hashish shares are impacting ETFs. For secure admission to to are residing and routine video from CNBC subscribe to CNBC PRO: This three hundred…